

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

13 Jun 2026

### Effect of vitamin D supplementation on inflammatory markers, liver function, lipid profile, body composition, and sonographic findings in patients with NAFLD

#### Protocol summary

##### Summary

Vitamin D is a fat-soluble molecule that is essential for calcium balance and bone. Prevalence of vitamin D deficiency in adults is about 5 to 30 percent. But this deficiency in patients with metabolic syndrome by about 75 percent. Nonalcoholic fatty liver pathological accumulation of fat in the liver in which there is no liver disease. The prevalence of the disease around the world is estimated at 10-35% in adults. Iran is estimated that 7% of children and 35 percent of adults are infected with non-alcoholic fatty liver. Nonalcoholic fatty liver is one of the components of metabolic syndrome. Studies of serum vitamin D levels associated with fatty liver there. According to the studies on the effect of vitamin D supplementation in patients with NAFLD has been. The objective of this study was to determine the effect of vitamin D supplementation on the recovery and improve the fat accumulation in the liver after liver enzymes in individuals with liver disease is ultrasound. This would be a parallel trial in which patients initially diagnosed with non-alcoholic fatty liver gastroenterologist are enrolled. Patients with NAFLD are not intervening in terms of age, sex and BMI matched with the experimental group are. In all patients, serum levels of vitamin D and liver function will be investigated. Vitamin D supplementation in the intervention group and the control group is given a placebo intervention. After 10 weeks, subjects of vitamin D levels and NAFLD are investigated.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2013060411763N8**

Registration date: **2013-09-12, 1392/06/21**

Registration timing: **retrospective**

Last update:

Update count: **0**

##### Registration date

2013-09-12, 1392/06/21

##### Registrant information

###### Name

Gholamreza Askari

###### Name of organization / entity

Isfahan University of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 31 1792 2110

###### Email address

askari@mui.ac.ir

##### Recruitment status

###### Recruitment complete

##### Funding source

Isfahan University of Medical Sciences

##### Expected recruitment start date

2012-06-20, 1391/03/31

##### Expected recruitment end date

2012-09-22, 1391/07/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Effect of vitamin D supplementation on inflammatory markers, liver function, lipid profile, body composition, and sonographic findings in patients with NAFLD

##### Public title

Effect of vitamin D supplementation on inflammatory

markers, liver function, lipid profile, body composition, and sonographic findings in patients with NAFLD

#### **Purpose**

Treatment

#### **Inclusion/Exclusion criteria**

Inclusion criteria were stable increases in AST and ALT greater than 50 U / L and metabolic syndrome, which includes waist circumference greater than 40 inches for men and greater than 35 inches for women, Triglycerides greater than or equal to 150 mg /dl, HDL less than 40 mg / dl for men and less than 50 mg/dl for women, Blood pressure greater than or equal to 85/135 mmHg, fasting blood glucose greater than or equal to 110 mg / dl. The participants in this study have not hepatitis C, B and Wilson disease and no history of chronic liver disease, a disease that affects the gallbladder and bile ducts. The absence of gestational, diabetes mellitus type 1 and 2, use of drugs affecting the levels of ALT (valproic acid, tamoxifen, HMG-COA reductase inhibitors, metformin, ACE 1 and ACER 1). They do not follow the diet and weight loss because weight loss effective vitamin d. Exclusion criteria included hospitalization, lack of cooperation in the study and with an acute illness.

#### **Age**

No age limit

#### **Gender**

Both

#### **Phase**

N/A

#### **Groups that have been masked**

No information

#### **Sample size**

Target sample size: 60

#### **Randomization (investigator's opinion)**

Randomized

#### **Randomization description**

#### **Blinding (investigator's opinion)**

Single blinded

#### **Blinding description**

#### **Placebo**

Used

#### **Assignment**

Parallel

#### **Other design features**

### **Secondary Ids**

empty

### **Ethics committees**

#### **1**

##### **Ethics committee**

###### **Name of ethics committee**

isfahan university medical science

###### **Street address**

isfahan

###### **City**

isfahan

###### **Postal code**

8174673461

#### **Approval date**

2012-06-09, 1391/03/20

#### **Ethics committee reference number**

391214

### **Health conditions studied**

#### **1**

##### **Description of health condition studied**

non alcoholic fatty liver disease

##### **ICD-10 code**

k76

##### **ICD-10 code description**

Other diseases of liver

### **Primary outcomes**

#### **1**

##### **Description**

The severity of fatty liver using abdominal ultrasound at baseline and end of study

##### **Timepoint**

Baseline and 10 weeks after intervention

##### **Method of measurement**

ultrasound

#### **2**

##### **Description**

AST and ALT liver enzymes

##### **Timepoint**

Baseline and 10 weeks after intervention

##### **Method of measurement**

Blood tests

### **Secondary outcomes**

#### **1**

##### **Description**

body composition

##### **Timepoint**

baseline and 10 weeks after intervention

##### **Method of measurement**

instrument body composition

#### **2**

##### **Description**

FBS

##### **Timepoint**

baseline and 10 weeks after intervention

##### **Method of measurement**

blood test

#### **3**

##### **Description**

lipid profile

##### **Timepoint**

baseline and 10 weeks after intervention

#### **Method of measurement**

blood test

### **4**

#### **Description**

CRP

#### **Timepoint**

baseline and 10 weeks after intervention

#### **Method of measurement**

blood test

## **Intervention groups**

### **1**

#### **Description**

This randomized clinical trial will be conducted in parallel. The objective of this study is the low number of participants in this study, 60 patients with NAFLD are referred to the Medical Research Center for Gastroenterology. The consent of the individuals participating in the study will be made in the experimental group during the 10-week study, which included a week Pearl vitamin D supplements are vitamin D 50,000 IU receive. The control group during the 10 weeks, each week placebo in terms of shape, color is similar to vitamin D supplements. The study followed patients for vitamin D supplement use, Weekly basis with the individuals contacted by telephone and SMS reminders to be a supplement to these people. To assess the level of acceptance of 25-hydroxy vitamin D supplements Gyy the size of the trucks will be used to study

#### **Category**

Treatment - Drugs

### **2**

#### **Description**

Placebo

#### **Category**

Placebo

## **Recruitment centers**

### **1**

#### **Recruitment center**

##### **Name of recruitment center**

clinic fatty liver

##### **Full name of responsible person**

mahdi forroughi

##### **Street address**

##### **City**

ifahan

## **Sponsors / Funding sources**

### **1**

#### **Sponsor**

##### **Name of organization / entity**

Food Security Research Center

##### **Full name of responsible person**

Dr askari

##### **Street address**

sfahan University of Medical Sciences, School Nutrition, Research Center on Food Security

##### **City**

isfahan

##### **Grant name**

##### **Grant code / Reference number**

##### **Is the source of funding the same sponsor organization/entity?**

Yes

##### **Title of funding source**

Food Security Research Center

##### **Proportion provided by this source**

100

##### **Public or private sector**

empty

##### **Domestic or foreign origin**

empty

##### **Category of foreign source of funding**

empty

##### **Country of origin**

##### **Type of organization providing the funding**

empty

## **Person responsible for general inquiries**

#### **Contact**

##### **Name of organization / entity**

food security research center

##### **Full name of responsible person**

mahdi foroughi

##### **Position**

msc student

##### **Other areas of specialty/work**

##### **Street address**

isfahan university medical science, school of nutrition

##### **City**

isfahan

##### **Postal code**

8174673461

##### **Phone**

+98 31 1523 6352

##### **Fax**

##### **Email**

MFOROGHI38@YAHOO.COMASKARI@MUI.AC.IR

##### **Web page address**

NUTR.MUI.AC.IR

## **Person responsible for scientific inquiries**

#### **Contact**

##### **Name of organization / entity**

isfahan university medical science, school of nutrition

##### **Full name of responsible person**

gholamreza askari

**Position**

assitance professor

**Other areas of specialty/work**

**Street address**

isfahan university medical science, school of nutrition

**City**

isfahan

**Postal code**

8174673461

**Phone**

+98 31 1792 2658

**Fax**

**Email**

askari@mui.ac.ir

**Web page address**

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

isfahan university medical science

**Full name of responsible person**

mahdi foroughi

**Position**

msc nutrition

**Other areas of specialty/work**

**Street address**

isfahan university medical science

**City**

isfahan

**Postal code**

8174673461

**Phone**

+98 31 1523 6352

**Fax**

**Email**

mforoghi38@yahoo.com

**Web page address**

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*